Back

One-month DAPT after biodegradable-polymer everolimus-eluting stent implantation in diabetic patients at high-bleeding risk: insights from the POEM trial

19 February 2026 (15:45 - 16:45)
Organised by: Logo
Congress Presentation Part of: Tailoring antithrombotic therapy after PCI: balancing ischaemic and bleeding risks Pharmacotherapy EAPCI Premium Access EAPCI Summit 2026 European Association of Percutaneous Cardiovascular Interventions (EAPCI)

About the speaker

Photo
Doctor Leon Gramss

Humanitas University, Milan (Italy)

6 More presentations in this session

Presentation thumbnail
Early oral anticoagulation monotherapy after PCI: insights from the POEM trial
Doctor C. Pivato (Milan, IT)
Abstract Slides
Presentation thumbnail
Utilisation and outcomes of dual antiplatelet therapy in patients with active cancer presenting with acute myocardial infarction: insights from the TriNetX global registry
Doctor A. Cole (Stoke on Trent, GB)
Abstract Slides
Presentation thumbnail
6 to 12-month vs. 1-month dual antiplatelet therapy: comparative outcomes after aspirin cessation with HT supreme stent in the pooled PIONEER III and PIONEER IV trial analysis
Professor Y. Onuma (Galway, IE)
Abstract Slides
Presentation thumbnail
Do the ARC-HBR criteria predict major bleeding and ischaemic events in an all-comer AMI population? Insights from the MINAP and SWEDEHEART registries
Doctor N. Weight (Stoke-on-Trent, GB)
Abstract Slides
Presentation thumbnail
Ticagrelor 60 mg vs. 90 mg in elderly ACS patients with vs. without diabetes undergoing percutaneous coronary intervention
Doctor A. Laino (Naples, IT)
Abstract Slides

Access the full session

Session thumbnail
Tailoring antithrombotic therapy after PCI: balancing ischaemic and bleeding risks

The Event

Event poster

EAPCI Summit 2026

19 February 2026 15:45 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources